Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Tom argues platinum chemotherapy, including gemcitabine-cisplatin, is inhibitory to immunotherapy, and he thinks most benefit in these perioperative trials comes from the adjuvant period. He notes survival curves separate mainly after chemotherapy stops, when some patients finally receive immune therapy alone. That timing suggests antagonism, not synergy, during chemo.

Related Insights

The success of neoadjuvant immunotherapy trials like Niagara and those with EV-Pembro means most patients will receive immune therapy before surgery. This fundamentally shifts the clinical landscape, making the question of starting adjuvant immunotherapy less relevant as perioperative treatment becomes the standard.

Multiple trials, including PACIFIC-2, have shown no survival benefit from adding immunotherapy concurrently with chemoradiation for unresectable Stage III NSCLC. This suggests that concurrent radiation may disrupt the immune-activating pathways necessary for immunotherapy to work, a critical lesson for future trial designs.

Retrospective data suggests that chemotherapy for localized MSI-high gastroesophageal cancer may be neutral or even deleterious. The concern is that it could blunt the patient's immune response, hindering the profound efficacy of checkpoint inhibitors in this specific subgroup. Experts are increasingly avoiding chemotherapy here.

Data from the Podium-303 trial's crossover arm suggests that waiting to use a PD-1 inhibitor after progression on chemotherapy is less effective than using it concurrently from the start. This supports the synergistic effect of chemo-immunotherapy and favors the concurrent approach as the standard of care.

A critical design flaw in most perioperative chemo-immunotherapy trials is the lack of a 'contribution of component' analysis. This makes it impossible to determine if the benefit comes from the neoadjuvant phase, the adjuvant phase, or both, thus complicating interpretation and clinical application.

While neoadjuvant-only immunotherapy has a strong rationale, a patient-level cross-trial comparison of CheckMate 816 (neoadjuvant) and 770T (perioperative) suggests the addition of adjuvant therapy improves event-free survival, favoring a full perioperative approach.

A leading hypothesis for why adding immunotherapy to chemoradiation failed is that radiation, particularly for central tumors, destroys the very lymphocytes immunotherapy aims to activate. This biological mechanism suggests the radiation essentially canceled out the drug's intended effect.

Carbone says Checkmate 227 used dual immunotherapy without chemotherapy and had almost exactly the same efficacy, including in PD-L1-negative subsets. He questions whether adding chemotherapy, especially four cycles, adds much benefit, and he notes that patients in his experience often like having only two cycles.

Clinical trial data suggests immunotherapy's timing is crucial in early-stage TNBC. Given with chemotherapy before surgery (neoadjuvant), it improves outcomes. However, when given alone after surgery (adjuvant), the IMPASSION 030 trial showed no benefit and was halted for futility, indicating pre-surgical tumor priming is essential.

Data from KEYNOTE-671 and other trials show that even patients achieving a pathological complete response (PCR) after neoadjuvant chemo-IO have better outcomes with the full perioperative regimen. This challenges the idea of de-escalating adjuvant therapy based on surgical pathology alone.

Gemcitabine-cisplatin may blunt immunotherapy's perioperative benefit | RiffOn